271 results on '"Hovey, Elizabeth"'
Search Results
52. Understanding sleep disturbance in the context of malignant brain tumors: a qualitative analysis
53. QOLP-23. PHASE II RANDOMISED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ACETAZOLAMIDE VERSUS PLACEBO FOR CEREBRAL OEDEMA IN RECURRENT AND/OR PROGRESSIVE HIGH-GRADE GLIOMA REQUIRING TREATMENT WITH DEXAMETHASONE
54. Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer
55. Exploring sleep disturbance among adults with primary or secondary malignant brain tumors and their caregivers
56. Sleep disturbance in people with brain tumours and caregivers: a survey of healthcare professionals’ views and current practice
57. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
58. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
59. 177Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
60. Experience with docetaxel in hormone-refractory prostate cancer (HRPC) at three Australian cancer centers: A retrospective study
61. Obscenity's meaning, smut-fighters, and contraception: 1872-1936.
62. Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma
63. Ongoing improvements in postoperative survival of glioblastoma in the temozolomide era: a population-based data linkage study
64. A case study of a long-term glioblastoma survivor with unmethylated MGMT and hypermutated genotype
65. Let's talk about cytotoxic chemotherapy dosing: unravelling adjustments and off‐protocol prescribing
66. PATH-11. TRANSLATING GENOMIC DATA OF GLIOBLASTOMA INTO CLINICAL PRACTICE: A CASE STUDY
67. RBTT-07. NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS
68. Understanding sleep disturbance in the context of malignant brain tumors: a qualitative analysis.
69. Exploring sleep disturbance among adults with primary or secondary malignant brain tumors and their caregivers.
70. Ongoing improvements in postoperative survival of glioblastoma in the temozolomide era: a population-based data linkage study.
71. What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial
72. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
73. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
74. Atypical Teratoid Rhabdoid Tumor: Two Case Reports and an Analysis of Adult Cases with Implications for Pathophysiology and Treatment
75. Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
76. Validating self-report and proxy reports of the Dexamethasone Symptom Questionnaire-Chronic for the evaluation of longer-term corticosteroid toxicity
77. Distress and psychological morbidity do not reduce over time in carers of patients with high-grade glioma
78. Do we really know who has an MGMTmethylated glioma? Results of an international survey regarding use of MGMTanalyses for glioma.
79. Concomitant Prostate Carcinoma and Follicular Lymphoma
80. Neuro-oncology practices in Australia: a Cooperative Group for Neuro-Oncology patterns of care study
81. Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial.
82. What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial
83. Carers of patients with high-grade glioma report high levels of distress, unmet needs, and psychological morbidity during patient chemoradiotherapy
84. Screening for Psychological Distress in Adult Primary Brain Tumor Patients and Caregivers: Considerations for Cancer Care Coordination
85. Glioblastoma in the elderly: making sense of the evidence
86. The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study
87. Patients' preferences for adjuvant sorafenib after resection of intermediate or high-risk renal cell carcinoma in the SORCE trial: What makes it worthwhile?
88. Incorporation of biomarkers in phase II studies of recurrent glioblastoma
89. Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial.
90. Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy
91. Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges
92. Neuro-oncology practices in Australia: A Cooperative Group for Neuro-Oncology patterns of care study
93. Glioblastoma in the elderly: making sense of the evidence.
94. Carers of patients with high-grade glioma report high levels of distress, unmet needs, and psychological morbidity during patient chemoradiotherapy.
95. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
96. Modafinil for fatigue associated with docetaxel-based chemotherapy: A randomized controlled trial.
97. Implementing patient question-prompt lists into routine cancer care
98. Estimation of an optimal chemotherapy utilisation rate for lung cancer: An evidence-based benchmark for cancer care
99. Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)
100. Culturally and linguistically diverse patient participation in glioma research.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.